v3.26.1
COMMON CONTROL MERGER (Tables)
12 Months Ended
Dec. 31, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Nika BioTechnology, Inc Consolidated Financial Statement
Cash $  322  
Inventory $  17,007  
Accruals $ (3,833 )
Due to related parties $ (109,877 )
Additional paid in capital $ (5,388,284 )
Accumulated deficit $ 5,464,629  
General and administrative expenses $ 20,036